We are live on ! Find out more
IMMX icon

Immix Biopharma
IMMX

25 hedge funds and large institutions have $6.1M invested in Immix Biopharma in 2024 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 7 increasing their positions, 4 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

550% more call options, than puts

Call options by funds: $13K | Put options by funds: $2K

75% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 4

1.86% less ownership

Funds ownership: 16.77% → 14.92% (-1.9%)

19% less funds holding

Funds holding: 31 → 25 (-6)

30% less capital invested

Capital invested by funds: $8.77M → $6.1M (-$2.67M)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 6

Holders
25
Holders Change
-6
Holders Change %
-19.35%
% of All Funds
0.36%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
7
Reduced
4
Closed
6
Calls
$13K
Puts
$2K
Net Calls
+$11K
Net Calls Change
+$11K

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$201K
2
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
+$169K
3
Morgan Stanley
Morgan Stanley
New York
+$52K
4
Geode Capital Management
Geode Capital Management
Massachusetts
+$16K
5
TAM
Tocqueville Asset Management
New York
+$11.1K

Top Sellers

Rank Fund Capital Flow
1
ACM
AIGH Capital Management
Maryland
-$570K
2
Renaissance Technologies
Renaissance Technologies
New York
-$306K
3
FIA
FNY Investment Advisers
New York
-$64K
4
PAG
Private Advisor Group
New Jersey
-$62.1K
5
Squarepoint
Squarepoint
New York
-$45.6K
Name Holding Trade Value Shares
Change 		Change in
Stake
ACM
1
AIGH Capital Management
Maryland
$1.67M -$570K -283,017 -20%
BL
2
Bleichroeder LP
New York
$1.27M – – –
CCC
3
Cable Car Capital
California
$1.19M – – –
Vanguard Group
4
Vanguard Group
Pennsylvania
$1.04M +$201K +100,000 +17%
Geode Capital Management
5
Geode Capital Management
Massachusetts
$224K +$16K +7,954 +6%
Morgan Stanley
6
Morgan Stanley
New York
$126K +$52K +25,856 +44%
Royal Bank of Canada
7
Royal Bank of Canada
Ontario, Canada
$125K +$169K +83,867 +63,058%
TAM
8
Tocqueville Asset Management
New York
$64.5K +$11.1K +5,500 +15%
State Street
9
State Street
Massachusetts
$64K – – –
Northern Trust
10
Northern Trust
Illinois
$58K – – –
PAG
11
Private Advisor Group
New Jersey
$51.1K -$62.1K -30,850 -47%
I
12
INVST
Indiana
$40.2K – – –
Commonwealth Equity Services
13
Commonwealth Equity Services
Massachusetts
$39K – – –
TW
14
TritonPoint Wealth
Maryland
$38.3K – – –
Millennium Management
15
Millennium Management
New York
$32.1K -$9.62K -4,779 -18%
BlackRock
16
BlackRock
New York
$20.9K +$1.1K +548 +4%
Focus Partners Wealth
17
Focus Partners Wealth
Massachusetts
$17.7K – – –
ONB
18
Old National Bancorp
Indiana
$14.9K – – –
UBS Group
19
UBS Group
Switzerland
$9.16K +$6.02K +2,992 +95%
TRCT
20
Tower Research Capital (TRC)
New York
$4.63K -$1.76K -876 -22%
SPIA
21
Steward Partners Investment Advisory
New York
$2.22K – – –
TIM
22
Tortoise Investment Management
New York
$1.94K – – –
Osaic Holdings
23
Osaic Holdings
Arizona
$1.42K – – –
Wells Fargo
24
Wells Fargo
California
$492 – – –
Bank of America
25
Bank of America
North Carolina
$171 – – –
1
2

IMMX Hedge Fund Activity: Q3 2024 in Review

25 of the 6,965 institutional investors tracked by Wall St. Rank reported a position in Immix Biopharma (IMMX) for Q3 2024, worth a combined $6.1M — down 30% from $8.77M a quarter earlier.

Sellers outnumbered buyers: 6 funds closed out of IMMX and 0 opened new positions — a net loss of 6 holders — while 4 trimmed existing stakes and 7 added.

The largest buyer was Vanguard Group, adding an estimated $201K. The largest seller was AIGH Capital Management, cutting an estimated $570K.

  • 25 institutional investors held Immix Biopharma (IMMX) as of Q3 2024, down from 31 in Q2 2024.
  • Funds reported $6.1M of Immix Biopharma stock for Q3 2024, down 30% quarter-over-quarter.
  • 0 funds opened new Immix Biopharma positions in Q3 2024 and 6 closed out, a net change of -6 holders.
  • The largest Immix Biopharma buyer in Q3 2024 was Vanguard Group, an estimated $201K added.
  • The largest Immix Biopharma seller in Q3 2024 was AIGH Capital Management, an estimated $570K sold.

Based on aggregated 13F filings for Q3 2024.